23981-47-7 | 2-(6-Methoxynaphthalen-2-yl)acetic acid

Packsize	Purity	Availability	Price	Discounted Price
5mg	96%	in stock	$42.00	$29.00
100mg	96%	in stock	$43.00	$30.00
250mg	96%	in stock	$53.00	$37.00
1g	96%	in stock	$98.00	$68.00
5g	96%	in stock	$369.00	$258.00
10g	96%	in stock	$665.00	$466.00
25g	96%	in stock	$1,317.00	$922.00

Description

• Catalog Number: AF30925
• Chemical Name: 2-(6-Methoxynaphthalen-2-yl)acetic acid
• CAS Number: 23981-47-7
• Molecular Formula: C13H12O3
• Molecular Weight: 216.2326
• MDL Number: MFCD00033105
• SMILES: COc1ccc2c(c1)ccc(c2)CC(=O)O

Computed Properties

• Complexity: 252
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 16
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 3
• XLogP3: 2.6

Literature

• Simultaneous determination of nabumetone and its principal metabolite in medicines and human urine by time-resolved fluorescence.

  The Analyst 20121107

• [Determination of nabumetone and 6-methoxy-2-naphthylacetic acid in plasma using HPLC with UV and MS detection].

  Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti 20110201

• In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone.

  Biological & pharmaceutical bulletin 20110101

• Rapid simultaneous determination of four non-steroidal anti-inflammatory drugs by means of derivative nonlinear variable-angle synchronous fluorescence spectrometry.

  Applied spectroscopy 20100801

• Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.

  Frontiers in pharmacology 20100101

• Applicability of LC/MS/MS assay for 6-methoxy-2-napthylacetic acid to support the bioequivalence study of nabumetone-comments on the research work of Patel et al. (2008).

  Biomedical chromatography : BMC 20090601

• A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes.

  Drug metabolism and disposition: the biological fate of chemicals 20090501

• Serum protein binding displacement: theoretical analysis using a hypothetical radiopharmaceutical and experimental analysis with 123I-N-isopropyl-p-iodoamphetamine.

  Nuclear medicine and biology 20090101

• High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study.

  Biomedical chromatography : BMC 20081101

• Effect of a nonprotein bioactive agent on the reduction of cyclooxygenase-2 and tumor necrosis factor-alpha in human intervertebral disc cells in vitro.

  Journal of neurosurgery. Spine 20081101

• Theoretical study of the phototoxicity of naproxen and the active form of nabumetone.

  The journal of physical chemistry. A 20081030

• Simultaneous determination of two anti-inflammatory drugs in serum using isopotential fluorimetry.

  Analytica chimica acta 20080905

• Safety of the nonselective NSAID nabumetone : focus on gastrointestinal tolerability.

  Drug safety 20080101

• Synthesis and evaluation of some gastrointestinal sparing anti-inflammatory aminoethyl ester derivatives of naphthalene-based NSAIDs.

  Archiv der Pharmazie 20070201

• Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure.

  Journal of medicinal chemistry 20060209

• Low direct cytotoxicity of nabumetone on gastric mucosal cells.

  Digestive diseases and sciences 20050901

• Photosensitizing properties of 6-methoxy-2-naphthylacetic acid, the major metabolite of the phototoxic non-steroidal anti-inflammatory and analgesic drug nabumetone.

  Die Pharmazie 20050801

• Simplex optimization of the variables affecting the micelle-stabilized room temperature phosphorescence of 6-methoxy-2-naphthylacetic acid and its kinetic determination in human urine.

  Analytical biochemistry 20050401

• Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints.

  Journal of medicinal chemistry 20040923

• Regulation of metalloproteinases and NF-kappaB activation in rabbit synovial fibroblasts via E prostaglandins and Erk: contrasting effects of nabumetone and 6MNA.

  British journal of pharmacology 20040701

• Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.

  Drugs 20040101

• Comparative biotransformation and disposition studies of nabumetone in humans and minipigs using high-performance liquid chromatography with ultraviolet, fluorescence and mass spectrometric detection.

  Journal of pharmaceutical and biomedical analysis 20030808

• Non-steroidal anti-inflammatory drug, nabumetone, prevents indometacin-induced gastric damage via inhibition of neutrophil functions.

  The Journal of pharmacy and pharmacology 20030201

• The role of cyclooxygenase-2 in lumbar disc herniation.

  Spine 20021115

• Evidence for the involvement of cyclooxygenase activity in the development of cocaine sensitization.

  Pharmacology, biochemistry, and behavior 20020101

• 2, 4-diamino-6- hydroxy pyrimidine inhibits NSAIDs induced nitrosyl-complex EPR signals and ulcer in rat jejunum.

  BMC gastroenterology 20020101

• Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo.

  Experimental nephrology 20010101